Your browser doesn't support javascript.
loading
Large scale application of the Finnish diabetes risk score in Latin American and Caribbean populations: a descriptive study.
Nieto-Martinez, Ramfis; Barengo, Noël C; Restrepo, Manuela; Grinspan, Augusto; Assefi, Aria; Mechanick, Jeffrey I.
Afiliação
  • Nieto-Martinez R; Departments of Global Health and Population and Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, United States.
  • Barengo NC; Precision Care Clinic Corp., Saint Cloud, FL, United States.
  • Restrepo M; Foundation for Clinic, Public Health, Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela.
  • Grinspan A; Department of Translational Medicine, Herbert Wertheim College of Medicine & Department of Global Health, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, United States.
  • Assefi A; Faculty of Medicine, Riga Stradins University, Riga, Latvia.
  • Mechanick JI; Medical Affairs Latin America, Merck Kommanditgesellschaft auf Aktien (KGaA), Darmstadt, Germany.
Front Endocrinol (Lausanne) ; 14: 1188784, 2023.
Article em En | MEDLINE | ID: mdl-37435487
ABSTRACT

Background:

The prevalence of type 2 diabetes (T2D) continues to increase in the Americas. Identifying people at risk for T2D is critical to the prevention of T2D complications, especially cardiovascular disease. This study gauges the ability to implement large population-based organized screening campaigns in 19 Latin American and Caribbean countries to detect people at risk for T2D using the Finnish Diabetes Risk Score (FINDRISC).

Methods:

This cross-sectional descriptive analysis uses data collected in a sample of men and women 18 years of age or older who completed FINDRISC via eHealth during a Guinness World Record attempt campaign between October 25 and November 1, 2021. FINDRISC is a non-invasive screening tool based on age, body mass index, waist circumference, physical activity, daily intake of fruits and vegetables, history of hyperglycemia, history of antihypertensive drug treatment, and family history of T2D, assigning a score ranging from 0 to 26 points. A cut-off point of ≥ 12 points was considered as high risk for T2D.

Results:

The final sample size consisted of 29,662 women (63%) and 17,605 men (27%). In total, 35% of subjects were at risk of T2D. The highest frequency rates (FINDRISC ≥ 12) were observed in Chile (39%), Central America (36.4%), and Peru (36.1%). Chile also had the highest proportion of people having a FINDRISC ≥15 points (25%), whereas the lowest was observed in Colombia (11.3%).

Conclusions:

FINDRISC can be easily implemented via eHealth technology over social networks in Latin American and Caribbean populations to detect people with high risk for T2D. Primary healthcare strategies are needed to perform T2D organized screening to deliver early, accessible, culturally sensitive, and sustainable interventions to prevent sequelae of T2D, and reduce the clinical and economic burden of cardiometabolic-based chronic disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Idioma: En Ano de publicação: 2023 Tipo de documento: Article